Zydus sets sight on US controlled substances market via Nesher buy
This article was originally published in Scrip
Zydus Cadila's acquisition of K-V Pharmaceutical's generic arm Nesher Pharmaceuticals and certain assets for about $60 million makes it among the very few Indian firms that are vying for a stronghold in the $7 billion US market for controlled substance medications.
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.